RxDoctor Payments Data

Anita Snyder

Family · West Chester, PANPI 1104966605

Payments from drug & device makers

$3,586in general payments, 2019–2025

Across 199 payments — averaging $18.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$482
  • Novo Nordisk$362
  • AstraZeneca$298
  • Astellas Pharma US Inc$298
  • Boehringer Ingelheim$248
  • Pfizer$177
  • plus $2K from 39 others

What the payments were for

  • Food & beverage$3,50198%
  • Education$852%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,586 in reported general payments places this provider in the 90th percentile of 4,717 family providers in Pennsylvania.

See all family providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$39,533
Medicare patients
271
Services billed
842

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin42$54,368
OzempicSemaglutide41$50,173
EliquisApixaban16$25,567
FarxigaDapagliflozin Propanediol30$24,214
Trelegy ElliptaFluticasone/Umeclidin/Vilanter15$12,210
Breo ElliptaFluticasone/Vilanterol19$11,020
Stiolto RespimatTiotropium Br/Olodaterol Hcl12$5,826
Arnuity ElliptaFluticasone Furoate16$3,674
Lisdexamfetamine Dimesylate12$3,071
SynthroidLevothyroxine Sodium28$2,469
Rosuvastatin Calcium139$2,161
Valsartan-HydrochlorothiazideValsartan/Hydrochlorothiazide45$2,146
Atorvastatin Calcium131$1,744
Valsartan44$1,729
Albuterol Sulfate HfaAlbuterol Sulfate55$1,544

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Stiolto Respimat$248$60,19454 claims
Novo NordiskOzempic$362$50,17341 claims
GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta$120$26,90550 claims
PfizerEliquis$177$25,56716 claims
AstraZenecaFarxiga$298$24,21430 claims
AbbVieSynthroid$482$2,46928 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$19$64461 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,717 family providers in Pennsylvania.

Other family in West Chester

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →